Autopsy report · NCT03212716

Efficiency of Antagonist Drugs of the Cellular Transcriptomic Signature of Influenza A Virus Infection.

“rate of inclusion and study affected by covid-19 epidemic”

The sponsor’s own words in the registry.

Life of this trial

• Registered 6 months before it started.
• Ran for about 4 years 4 months before it stopped.
• 85 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

University Hospital, Lille

Sponsor type

University, hospital or other

Conditions

Flu

Interventions

Oseltamivir; Diltiazem; Placebos

Participants

85

Sites

19

Countries

France

Trials that died the same way

• Ivermectin in Adults With Severe COVID-19.
  “Lack of severe COVID-19 cases in the place of study” (73% match in meaning)
• The Use of a Point-of-care Thoracic Ultrasound Protocol for Hospital Medical Emergency Teams
  “Slow inclusion rate (partly due to Covid-19)” (73% match in meaning)
• Novel SARS-CoV-2 Point-of-care Testing
  “failure in enrolling eligible subjects during COVID-19 outbreaks” (73% match in meaning)
• Characterizing Biomarkers of Early Parkinson's Disease Progression (TREG)
  “COVID-19 Research Restrictions” (72% match in meaning)
• High-frequency vs. Low-frequency vs. Sham DMPFC-rTMS for Bulimia and Anorexia Nervosa
  “COVID-19 pandemic restrictions.” (71% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.